Stilla Technologies: Ruth Szedbries
Stilla Technologies has appointed Ruth Szebries as general manager and VP of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as the firm's senior director for global market development.
Grail: Matthew Young
Grail has appointed Matthew Young as chief operating officer. Young joins Grail from Jazz Pharmaceuticals, where he most recently served as executive VP and CFO. Prior to Jazz, Young worked in investment banking for about 20 years in positions at Barclays Capital, Citigroup Global Markets, and Lehman Brothers. He currently is a board member at PRA Health Sciences. Young is also a lead independent director and chairman of the audit committee of CytomX Therapeutics.
Biodesix: James Jett
Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.